Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
Yu-Hsuan Joni ShaoJian-Hua HongChun-Kai ChenChao-Yuan HuangPublished in: Prostate cancer and prostatic diseases (2022)
In patients with PCa and pre-existing CVD, GnRH antagonist use was associated with lower risks for composite CV events and MACE compared with GnRHa.